95 related articles for article (PubMed ID: 29125105)
21. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children.
Lau YL; Vessey SJ; Chan IS; Lee TL; Huang LM; Lee CY; Lin TY; Lee BW; Kwan K; Kasim SM; Chan CY; Kaplan KM; Distefano DJ; Harmon AL; Golie A; Hartzel J; Xu J; Li S; Matthews H; Sadoff JC; Shaw A
Vaccine; 2002 Jul; 20(23-24):2942-9. PubMed ID: 12126906
[TBL] [Abstract][Full Text] [Related]
22. Sequencing and characterization of Varicella-zoster virus vaccine strain SuduVax.
Kim JI; Jung GS; Kim YY; Ji GY; Kim HS; Wang WD; Park HS; Park SY; Kim GH; Kwon SN; Lee KM; Ahn JH; Yoon Y; Lee CH
Virol J; 2011 Dec; 8():547. PubMed ID: 22176950
[TBL] [Abstract][Full Text] [Related]
23. Worldwide experience with the Oka-strain live varicella vaccine.
Andre FE
Postgrad Med J; 1985; 61 Suppl 4():113-20. PubMed ID: 3014468
[TBL] [Abstract][Full Text] [Related]
24. Population diversity in batches of the varicella Oka vaccine.
Kanda RK; Quinlivan ML; Gershon AA; Nichols RA; Breuer J
Vaccine; 2011 Apr; 29(17):3293-8. PubMed ID: 21349363
[TBL] [Abstract][Full Text] [Related]
25. Varivax (Merck & Co).
Jones T
Curr Opin Investig Drugs; 2002 Jan; 3(1):54-7. PubMed ID: 12054073
[TBL] [Abstract][Full Text] [Related]
26. Comparative analyses of the 9 glycoprotein genes found in wild-type and vaccine strains of varicella-zoster virus.
Storlie J; Maresova L; Jackson W; Grose C
J Infect Dis; 2008 Mar; 197 Suppl 2():S49-53. PubMed ID: 18419408
[TBL] [Abstract][Full Text] [Related]
27. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).
Goulleret N; Mauvisseau E; Essevaz-Roulet M; Quinlivan M; Breuer J
Vaccine; 2010 Aug; 28(36):5878-82. PubMed ID: 20600487
[TBL] [Abstract][Full Text] [Related]
28. Production and quality control of the Oka-strain live varicella vaccine.
D'Hondt E; Berge E; Colinet G; Duchene M; Peetermans J
Postgrad Med J; 1985; 61 Suppl 4():53-6. PubMed ID: 3014478
[TBL] [Abstract][Full Text] [Related]
29. Amplification and sequencing of varicella-zoster virus (VZV) gene 4: point mutation in a VZV strain causing chickenpox during pregnancy.
Chow VT; Lim KP
Acta Virol; 1997 Oct; 41(5):277-83. PubMed ID: 9607081
[TBL] [Abstract][Full Text] [Related]
30. [Varicella-zoster virus].
Yoshikawa T; Nishiyama Y
Nihon Rinsho; 2003 Mar; 61 Suppl 3():575-81. PubMed ID: 12718031
[No Abstract] [Full Text] [Related]
31. [Vaccines against varicella-zoster virus (VZV)].
Salleras L; Salleras M; Soldevila N; Prat A; Garrido P; Domínguez Á
Enferm Infecc Microbiol Clin; 2015; 33(6):411-23. PubMed ID: 26096575
[TBL] [Abstract][Full Text] [Related]
32. Stable and consistent genetic profile of Oka varicella vaccine virus is not linked with appearance of infrequent breakthrough cases postvaccination.
Vassilev V
J Clin Microbiol; 2005 Oct; 43(10):5415-6; author reply 5416-7. PubMed ID: 16208038
[No Abstract] [Full Text] [Related]
33. Analysis of repeat units in the R2 region among different Oka varicella-zoster virus vaccine strains and wild-type strains in Germany.
Sauerbrei A; Zell R; Wutzler P
Intervirology; 2007; 50(1):40-4. PubMed ID: 17164556
[TBL] [Abstract][Full Text] [Related]
34. [Genetic characteristics of varicella zoster virus in Shandong province from 2020 to 2021].
Chen M; Wang ST; Liu Y; Xiong P; Tao ZX; Zhang L; Jia JL; Wang CY; Xu S
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Aug; 56(8):1080-1086. PubMed ID: 35922235
[No Abstract] [Full Text] [Related]
35. Enhancement of varicella-zoster virus infection in cell lines expressing ORF4- or ORF62-encoded proteins.
Schoonbroodt S; Piette J; Baudoux L; Defechereux P; Rentier B; Merville MP
J Med Virol; 1996 Aug; 49(4):264-73. PubMed ID: 8877757
[TBL] [Abstract][Full Text] [Related]
36. Analysis of single nucleotide polymorphism among Varicella-Zoster Virus and identification of vaccine-specific sites.
Jeon JS; Won YH; Kim IK; Ahn JH; Shin OS; Kim JH; Lee CH
Virology; 2016 Sep; 496():277-286. PubMed ID: 27376245
[TBL] [Abstract][Full Text] [Related]
37. Vaccine Oka variants and sequence variability in vaccine-related skin lesions.
Breuer J; Schmid DS
J Infect Dis; 2008 Mar; 197 Suppl 2():S54-7. PubMed ID: 18419409
[TBL] [Abstract][Full Text] [Related]
38. Comparison of performance of varicella vaccines via infectious disease modeling.
Pillsbury M; Carias C; Samant S; Greenberg D; Pawaskar M
Vaccine; 2022 Jun; 40(29):3954-3962. PubMed ID: 35660037
[TBL] [Abstract][Full Text] [Related]
39. Vaccine Oka varicella-zoster virus genotypes are monomorphic in single vesicles and polymorphic in respiratory tract secretions.
Quinlivan MA; Gershon AA; Nichols RA; La Russa P; Steinberg SP; Breuer J
J Infect Dis; 2006 Apr; 193(7):927-30. PubMed ID: 16518753
[TBL] [Abstract][Full Text] [Related]
40. Varicella vaccine in post-exposure prophylaxis.
Ferson MJ
Commun Dis Intell; 2001 Jan; 25(1):13-5. PubMed ID: 11280194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
